J&J, HRSA at Loggerheads Over 340B Drug Pricing for Stelara and Xarelto

Johnson & Johnson’s proposed changes to the hospital drug discount program are inconsistent with the federal statute, according to the Health Resources and Services Administration.

Scroll to Top